5 active not recruiting, 2 enrolling by invitation, 2 recruiting, 1 completed. 11 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Active not recruiting 5, Enrolling by invitation 2, Recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Immunoglobulin A Nephropathy: new trials by email Literature Review of Immunoglobulin A Nephropathy trials Research Report on Immunoglobulin A Nephropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled Syringe Povetacicept, Sibeprenlimab - Immunoglobulin A Nephropathy | Phase 3 | Not yet recruiting | Vertex Pharmaceuticals Incorporated | 40 | 2026-10-23 | 2026-10-22 |
| A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy Povetacicept - Immunoglobulin A Nephropathy | Phase 3 | Enrolling by invitation | Vertex Pharmaceuticals Incorporated | 605 | 2026-09-17 | 2026-10-19 |
| Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN Drug: Atrasentan - Berger Disease, Bergers Disease | Phase 3 | Recruiting | Novartis Pharmaceuticals | 28 | 2026-08-06 | 2026-10-15 |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN Ravulizumab - IgAN, IgAVN | Phase 3 | Recruiting | Alexion Pharmaceuticals, Inc. | 36 | 2025-06-14 | 2026-07-30 |
| Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) Povetacicept, Placebo (matched to Povetacicept) - Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 605 | 2024-08-30 | 2026-05-15 |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Ravulizumab, Placebo - Immunoglobulin A Nephropathy, IgAN | Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 584 | 2024-03-29 | 2026-10-02 |
| A Study of Zigakibart in Adults With IgA Nephropathy BION-1301, Placebo - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 383 | 2023-07-06 | 2026-04-01 |
| Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Sibeprenlimab 400 mg s.c. Q4weeks - Immunoglobulin A Nephropathy | Phase 2 / Phase 3 | Enrolling by invitation | Otsuka Pharmaceutical Development & Commercialization, Inc. | 600 | 2022-04-05 | 2026-05-05 |
| Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN) Sibeprenlimab 400 mg, Placebo - Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 530 | 2022-03-15 | 2026-07-14 |
| Atrasentan in Patients With IgA Nephropathy Atrasentan, Placebo, Zigakibart - IgA Nephropathy, Immunoglobulin A Nephropathy | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 404 | 2020-12-11 | 2026-06-04 |
| A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy sparsentan, irbesartan, Dapagliflozin - Immunoglobulin A Nephropathy | Phase 3 | Completed | Travere Therapeutics, Inc. | 406 | 2018-12-11 | 2026-10-14 |
Glomerulonephritis, IGA (11) · Glomerulonephritis (4) · Renal Insufficiency, Chronic (4) · Kidney Diseases (3) · Urologic Diseases (3) · Proteinuria (2) · IgA Vasculitis (1)
Autoimmune Diseases (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Immune System Diseases (11) · Male Urogenital Diseases (11) · Nephritis (11) · Urogenital Diseases (11) · Kidney Diseases (8) · Urologic Diseases (8) · Glomerulonephritis (7) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Chronic Disease (4) · Disease Attributes (4) · Renal Insufficiency (4)
Atrasentan (2) · ravulizumab (2) · Irbesartan (1) · dapagliflozin (1) · sparsentan (1)
Novartis Pharmaceuticals (3) · Alexion Pharmaceuticals, Inc. (2) · Otsuka Pharmaceutical Development & Commercialization, Inc. (2) · Vertex Pharmaceuticals Incorporated (2) · Alpine Immune Sciences Inc, A Subsidiary of Vertex (1) · Travere Therapeutics, Inc. (1)
United States (10) · South Korea (9) · Spain (9) · Taiwan (9) · China (8) · France (8) · Italy (8) · Japan (8) · Australia (7) · Germany (7) · United Kingdom (7) · Belgium (6) · Brazil (6) · Canada (6) · Czechia (6)
PMID 38299639, PMID 40465397, PMID 37015244, PMID 37254256, PMID 37931634, PMID 38059359, PMID 39455063, PMID 39460694, PMID 40482854, PMID 41211929, PMID 41426046, PMID 41428405, PMID 41442197, PMID 42205925, PMID 42242268, PMID 42384439, PMID 42633049
2017 (1), 2023 (1), 2025 (1)